Previous 10 | Next 10 |
– Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose – – Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe – SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology...
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the virtual SVB Securities Global Biopharma Confe...
Summary Kura Oncology, Inc. has two assets, and both produced decent data. Each asset has its own set of problems. Kura Oncology is set for cash. I covered Kura Oncology, Inc. ( KURA ) two years ago, when I said that, although I like the company’s science, p...
Cancer-focused biotech Kura Oncology ( NASDAQ: KURA ) announced Tuesday the FDA clearance of its Investigational New Drug (IND) application for solid tumor candidate KO-2806. The company expects to start the first-in-human study for KO-2806 as a Phase 1 trial in Q3 2023 to test its ef...
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the In...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Kura Oncology ( NASDAQ: KURA ) fell ~14% on Monday after the clinical-stage biotech announced updated data from a Phase 1/2 trial for lead asset ziftomenib in patients with relapsed/refractory acute myeloid leukemia (AML) Meanwhile, Kura’s rival for menin-targeting cancer t...
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML – – Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg – – 600 mg determined as recommended Phas...
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will host an investor event featuring members of the Kura mana...
Summary Today, we look back in on small cap developmental concern Kura Oncology for the first time in two years. Last week, the company reported third quarter results and got a $25 million equity investment from drug giant Bristol Myers Squibb. An investment analysis follows i...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...